Global Immuno-Oncology Market By Therapy, (Immune Checkpoint Inhibitors, Monoclonal Antibodies (mAbs), Cell & Gene Therapies, Cancer Vaccines, Oncolytic Virus Therapy, Combination Therapies), By Indication (Solid Tumours, Hematologic Malignancies), By Stage/ Line of Therapy (First-line (frontline), Second-line, Third-line/later lines, Adjuvant (post-surgery), Neoadjuvant (pre-surgery)), By Distribution Channel (Hospital pharmacies, Retail pharmacies, and Online pharmacies), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034
- Published date: Oct 2025
- Report ID: 143626
- Number of Pages: 250
- Format:
-
keyboard_arrow_up
-
-
- Merck & Co.
- Bristol-Myers Squibb (BMS)
- Roche Holding AG Company Profile
- AstraZeneca Plc Company Profile
- Novartis AG Company Profile
- Pfizer Inc Company Profile
- Amgen Inc.
- Sanofi S.A.
- Gilead Sciences (Kite Pharma)
- Eli Lilly and Company
- Takeda Pharmaceutical Company
- GlaxoSmithKline (GSK)
- Incyte Corporation
- Johnson & Johnson
- Bayer AG Company Profile
- Genmab A/S
- Regeneron Pharmaceuticals
- BeiGene Ltd.
- Other key players
Our Clients
✖
Request a Sample Report
We'll get back to you as quickly as possible



